Which domestic manufacturers produce Lynparza? How is the quality?

Olaparib is a PARP inhibitor that is widely used to treat solid tumors such as BRCA mutation-related ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer. As the first approved oral PARP inhibitor anti-tumor drug, olaparib was jointly developed by AstraZeneca and MSD. Its trade name is Lynparza. It has been approved and marketed in China by the National Medical Products Administration. The original drug has strict quality standards, sophisticated manufacturing technology, clear efficacy in long-term clinical use, and abundant safety data. It is one of the most widely used targeted drugs in current clinical treatment.

With the gradual liberalization of generic drug policies and the state's encouragement of high-quality generic drugs to replace imports, domestic companies have also completed the development of generic Lynparza. Among them, the generic version of olaparib launched by Qilu Pharmaceutical is called "Zipani" and has been approved for marketing and officially sold. Judging from the registration data and public information, Zipanib uses the same active ingredients and formulation process as the original drug, and complies with the national generic drug consistency evaluation standards, which means that it should be highly consistent with the original drug in terms of key efficacy, bioavailability and in vivo absorption kinetics. Against the background of the gradual implementation of domestic medical insurance policies, the introduction of generic drugs has also provided patients with more affordable and accessible treatment options.

In terms of drug quality, domestic generic drugs such as Olaparib produced by Qilu Pharmaceutical have passed strict national review and are being used in many tertiary hospitals, with stable feedback. Although there is still a gap between it and the original drug in terms of accumulation of international clinical data, from a pharmacological perspective and drug standards, the two are highly similar. For patient groups with heavy financial burdens, the launch of domestically produced Lynparza will help break the monopoly of original drugs and reduce treatment costs.

Reference materials:https://www.lynparza.com/